Efficacy you can see
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
See the difference Taltz can make in 12 weeks4-7
Copying, downloading, or other use of patient photos is expressly prohibited.
Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.
PASI 75
PATIENT AT BASELINE
(PASI SCORE=19.2)
PATIENT AT WEEK 12
(PASI SCORE=2.8)
Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.
SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE
During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn’s disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn’s disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
See the difference Taltz can make in 12 weeks4-7
Copying, downloading, or other use of patient photos is expressly prohibited.
Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.
PASI 90
PATIENT AT BASELINE
(PASI SCORE=32.5)
PATIENT AT WEEK 12
(PASI SCORE=2.3)
Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.
SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
See the difference Taltz can make in 12 weeks4-7
Copying, downloading, or other use of patient photos is expressly prohibited.
Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.
PASI 100
PATIENT AT BASELINE
(PASI SCORE=13)
PATIENT AT WEEK 12
(PASI SCORE=0)
Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.
SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
See the difference Taltz can make in 12 weeks4-7
Copying, downloading, or other use of patient photos is expressly prohibited.
Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.
PASI SPGA 0,1
PATIENT AT BASELINE
(PASI SCORE=4)
PATIENT AT WEEK 12
(PASI SCORE=1)
Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.
SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
